Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study

Vascul Pharmacol. 2017 Dec:99:45-52. doi: 10.1016/j.vph.2017.09.005. Epub 2017 Sep 23.

Abstract

Background: Statins and sartans can, in therapeutic doses, induce pleiotropic cardiovascular effects. Similar has recently been shown also for sub-therapeutic doses. We thus explored and compared the cardiovascular pleiotropic efficacy of sub-therapeutic vs. therapeutic doses.

Methods: Wistar rats were randomly divided into 7 groups receiving fluvastatin, valsartan and their combination in sub-therapeutic and therapeutic doses, or saline. After 6weeks, the animals were euthanised, their hearts and thoracic aortas isolated, and blood samples taken. Endothelium-dependent relaxation of the thoracic aortae and ischaemic-reperfusion injury of the isolated hearts were assessed along with the related serum parameters and genes expression.

Results: Fluvastatin and valsartan alone or in combination were significantly more effective in sub-therapeutic than therapeutic doses. The sub-therapeutic combination greatly increased thoracic aorta endothelium-dependent relaxation and maximally protected the isolated hearts against ischaemia-reperfusion injury and was thus most effective. Beneficial effects were accompanied by increased levels of nitric oxide (NO) and decreased levels of asymmetric dimethylarginine (ADMA) in the serum (again prominently induced by the sub-therapeutic combination). Furthermore, nitric oxide synthase 3 (NOS3) and endothelin receptor type A (EDNRA) genes expression increased, but only in both combination groups and without significant differences between them. In the therapeutic dose groups, fluvastatin and valsartan decreased cholesterol values and systolic blood pressure.

Conclusion: Sub-therapeutic doses of fluvastatin and valsartan are more effective in expressing cardiovascular pleiotropic effects than therapeutic doses of fluvastatin and/or valsartan. These results could be of significant clinical relevance.

Keywords: Combination; Endothelium-dependent relaxation; Ischaemia-reperfusion injury; Rats; Sartans; Statins; Sub-therapeutic doses; Therapeutic doses.

Publication types

  • Comparative Study

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / administration & dosage*
  • Animals
  • Aorta, Thoracic / drug effects*
  • Aorta, Thoracic / metabolism
  • Aorta, Thoracic / physiopathology
  • Arginine / analogs & derivatives
  • Arginine / blood
  • Blood Pressure / drug effects
  • Cholesterol / blood
  • Coronary Circulation / drug effects
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Fatty Acids, Monounsaturated / administration & dosage*
  • Female
  • Fluvastatin
  • Heart / drug effects*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
  • In Vitro Techniques
  • Indoles / administration & dosage*
  • Male
  • Myocardial Reperfusion Injury / blood
  • Myocardial Reperfusion Injury / pathology
  • Myocardial Reperfusion Injury / physiopathology
  • Myocardial Reperfusion Injury / prevention & control*
  • Myocardium / metabolism
  • Myocardium / pathology
  • Nitric Oxide / blood
  • Nitric Oxide Synthase Type III / genetics
  • Nitric Oxide Synthase Type III / metabolism
  • Rats, Wistar
  • Receptor, Endothelin A / genetics
  • Receptor, Endothelin A / metabolism
  • Time Factors
  • Valsartan / administration & dosage*
  • Vasodilation / drug effects

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Fatty Acids, Monounsaturated
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Indoles
  • Receptor, Endothelin A
  • Nitric Oxide
  • Fluvastatin
  • N,N-dimethylarginine
  • Valsartan
  • Arginine
  • Cholesterol
  • Nitric Oxide Synthase Type III
  • Nos3 protein, rat